SLV-154 Treatment for Advanced Cancers
This study is testing a new treatment called SLV-154 for people with advanced solid tumors or metastatic (spread) cancer. SLV-154 works as both an immunotherapy (helps your immune system fight cancer) and a targeted therapy (focuses on specific cancer cells). The study aims to find the safest and most effective dose of SLV-154 and see how well it shrinks tumors. You might be able to join if you are at least 12 years old, have advanced cancer that has spread or come back, and your cancer can be measured on scans. The study is currently unclear on its recruitment status, but plans to enroll about 250 participants.
- Study design
- This is a Phase 1 study with two parts: a dose-finding part (Phase 1a) and an expansion part (Phase 1b). It plans to include around 250 participants.
- What's involved
- SLV-154 will be given through a vein (intravenously) in repeated 3-week cycles. Treatment will continue until your disease gets worse or you stop treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how well the treatment works and its safety for up to about 18 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SLV-154 Treatment of Advanced Cancers
At a glance
Conditions
NCT06771219
Where you'd take part
This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Astera Cancer Care
East Brunswick, New Jerseystudy coordinator listed
Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, Californiastudy coordinator listed
Recruiting
Mays Cancer Center; University of Texas Health San Antonio
San Antonio, Texasstudy coordinator listed
Recruiting
MD Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New Yorkstudy coordinator listed
Recruiting
Northwest Medical Specialties, PLLC
Tacoma, Washingtonstudy coordinator listed
Recruiting
Oncology Consultants
Houston, Texasstudy coordinator listed
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohiostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Phase 1a: MTD and/or RDRThrough the duration of treatment, up to approximately 18 months
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154.
- Phase 1b: Objective response rate (ORR)Through the duration of treatment, up to approximately 18 months
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).